In 1969 Themis was founded on a path-breaking partnership with Gedeon Richter Ltd., Hungary. From the start, partnerships are what givs us strength.
Themis has manufacturing and marketing arrangements with leading MNCs for within the country.
How does it work for our Partners
Marketing, distribution and even product incubation are areas that are ripe for collaboration.
Ready availability of a large range of innovative formulations
Our growing basket of differentiated injectables, API and other products re proven in varied markets and have a high acceptance with health-care experts. The benefits of our PPT (Patented Platform Technology) – incisive products that are break-throughs, faster product development cycles and highly detailed documentation of results and trails – are available for our partners. We ensure the that there is focus on core issues of critical therapies, so our partners can focus on market expansion.
Our manufacturing facilities are WHO-GMP Certified. Besides this we have exclusive tie-ups with sites having EUGMP, USFDA, PICS, MHRA approved facilities.
Our four state-of-the-art manufacturing plants are process driven. Our investment in improving technology, enhancing training and bettering manufacturing processes is continuous. The factory technicians are skilled and the adherence to production schedules is clock-work. Our distribution and delivery support is deadline-driven, quality-controlled and absolutely as promised.
In the final analysis, beyond the numbers, what we look for in partners is a shared concern and that is the enhancement of human health.
We want to take the world from pain to pain-free parentals through pain free work on dedicated innovations. Emal – the first in the world injectable against critical malaria, Etojet – the worlds first painless Etrocoxib injection and a first of its kinds injectable.
Diclofenac sodium for pain relief, are all a result of pursuit of ideas taken to their full potential. Our aim is to make disease management easier and painless for both patients and healthcare professionals.
- lntimation under regulation 39(3) of Securities and Exchanae Board of India (Listinq Obligations and Disclosure Requirements) Requlation, 2015 [“SEBI (LODR) Regulations, 2015″] 07/Mar/2019
- Outcome of Board Meeting – 08 Feb 2019 08/Feb/2019
- Intimation of Board Meeting – 08 Feb 2019 25/Jan/2019
- Postal Ballot Result 31-Dec-2018 31/Dec/2018
- Postal Ballot Notice & Form 29/Nov/2018
11/12, Udyog Nagar,
S. V. Road, Goregaon (W),